# GAIA (NCT02950051)

> Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02950051
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: German CLL Study Group
- Conditions: Chronic Lymphocytic Leukemia
- Interventions: Fludarabine; Cyclophosphamide; Rituximab; Bendamustine; Venetoclax; Obinutuzumab; Ibrutinib
- Enrollment: 926
- Primary outcome: Miminimal residual disease (MRD) negativity rate in peripheral blood (PB)
- Primary outcome: Progression free survival (PFS)

## Commentary we found

- YouTube: 69
- Podcasts: 48
- X threads: 25

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=gaia-nct02950051

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02950051", "email": "<work email>"}; the inbox owner confirms by the emailed link.